Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$0.00-100.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Daniel J. O'Connell
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 61
- Beta
- 0.33
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -6.67
Financials
Revenue
$0.00-100.0%Net Income
$-32.72MEBITDA
$-31.44MFree Cash Flow
$-18.07MEPS (diluted)
$-0.45Shares Outstanding (diluted)
72.25M+152.2%Operating Expenses
$32.56MCash & Debt
$110.20MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-121.33M | $-2.00 |
| 2024 | $0.00 | $-102.33M | $-1.71 |
| 2023 | $0.00 | $-52.37M | $-1.08 |
| 2022 | $0.00 | $-42.86M | $-1.06 |
| 2021 | $0.00 | $-100.61M | $-2.63 |
| 2020 | $1.44M | $-7.33M | $-0.26 |
| 2019 | $1.70M | $-7.91M | $-0.20 |
Valuation
ABOShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-93.33%Social Signal Score
Mentions (6)
- Newszacks.com·14d ago·Negative
4 Alzheimer's Drug Stocks to Watch on World Alzheimer's Day Four biotech stocks advance Alzheimer's therapies, from marketed treatments to experimental programs targeting amyloid and tau.
View source ↗ - Newsseekingalpha.com·19d ago·Positive
Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript Acumen Pharmaceuticals, Inc. (ABOS) Analyst/Investor Day Transcript
View source ↗ - Newsglobenewswire.com·25d ago·Neutral
Acumen Pharmaceuticals to Hold Virtual Investor Day on September 16, 2026 NEWTON, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, announced today that the Company will host a virtual Investor Day on Wednesday, September 16, 2026 at 10:00 a.m. ET.
View source ↗ - Newsseekingalpha.com·25d ago·Positive
Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Acumen Pharmaceuticals, Inc. (ABOS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsmarketbeat.com·55d ago·Neutral
Acumen Pharmaceuticals Q2 Earnings Call Highlights Acumen Pharmaceuticals NASDAQ: ABOS said it remains on track to report top-line results late in 2026 from its Phase II ALTITUDE-AD study of sabirnetug, an investigational antibody designed to selectively target synaptotoxic amyloid-beta oligomers in early Alzheimer's disease.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights NEWTON, Mass., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's disease (AD), today reported financial results for the second quarter of 2026 and provided a business update.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-0.43 per share
Typical surprise +14.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.45 vs $-0.36miss
- Tue, May 12$-0.33 vs $-0.40beat
- Thu, Mar 26$-0.41 vs $-0.50beat
- Wed, Nov 12$-0.44 vs $-0.63beat
- Tue, Aug 12$-0.68 vs $-0.54miss
- Tue, May 13$-0.48 vs $-0.56beat
Estimates and results for ABOS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ABOS officers and directors.
- Bought
- —
- Sold
- $625k
0 trades
48 trades
- Porter Derrellsold
- Porter Derrellsold
- Porter Derrellsold
- Fountain Nathan Bsold
- Meisner Derek Msold
- Meisner Derek Msold
- Meisner Derek Msold
- Meisner Derek Msold
52 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ABOS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.